BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

...was also an investor in AveXis, which Novartis (NYSE:NVS...
BioCentury | Apr 7, 2021
Deals

Radioligand target deal with Novartis expands Artios’ runway and remit

...lethality By Paul Bonanos, Associate Editor Synthetic lethality company Artios is the latest beneficiary of Novartis’...
...larger biopharmas entered deals with synthetic lethality companies including Artios Pharma Ltd. during 2020, while Novartis AG...
...collateral toxicity because the radioligand’s effects are specific to a tumor.Cambridge, U.K.-based Artios said the Novartis...
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

...responsible for product commercialization operations in the region. Frame held several senior leadership roles at Novartis AG...
BioCentury | Apr 6, 2021
Finance

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

...selectivity is a differentiator from other ALDOS programs. Congleton said an earlier therapy developed by Novartis AG...
...at ProQR Therapeutics N.V. (NASDAQ:PRQR), miRagen Therapeutics Inc. (NASDAQ:MGEN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as well as Novartis...
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

...years ago. Sales of Kymriah tisagenlecleucel from Novartis AG...
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...roughly in the same league as its partnerships with Eli Lilly and Co. (NYSE:LLY) and Novartis AG...
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

...By BioCentury Staff The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms...
...XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Xcopri, cenobamate (YKP3089) Cara Therapeutics Inc. Vifor Pharma Ltd. AbbVie Inc. Novartis AG F...
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...managed by Morgan Stanley’s Counterpoint Global, new strategic investor Illumina Inc. (NASDAQ:ILMN) and existing strategic investor Novartis AG...
BioCentury | Mar 28, 2021
Finance

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

...are reversible menin inhibitors, according to Biomea Fusion’s prospectus.Bayer AG (Xetra:BAYN), Johnson & Johnson (NYSE:JNJ), Novartis AG...
BioCentury | Mar 26, 2021
Product Development

Three’s a crowd in SMA sales: Data Byte

...Durkin Wolfe, ASSOCIATE Editor, DATA & Analytics Novartis...
...site was never licensed to manufacture the drug. Novartis AG...
Items per page:
1 - 10 of 10626
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

...was also an investor in AveXis, which Novartis (NYSE:NVS...
BioCentury | Apr 7, 2021
Deals

Radioligand target deal with Novartis expands Artios’ runway and remit

...lethality By Paul Bonanos, Associate Editor Synthetic lethality company Artios is the latest beneficiary of Novartis’...
...larger biopharmas entered deals with synthetic lethality companies including Artios Pharma Ltd. during 2020, while Novartis AG...
...collateral toxicity because the radioligand’s effects are specific to a tumor.Cambridge, U.K.-based Artios said the Novartis...
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

...responsible for product commercialization operations in the region. Frame held several senior leadership roles at Novartis AG...
BioCentury | Apr 6, 2021
Finance

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

...selectivity is a differentiator from other ALDOS programs. Congleton said an earlier therapy developed by Novartis AG...
...at ProQR Therapeutics N.V. (NASDAQ:PRQR), miRagen Therapeutics Inc. (NASDAQ:MGEN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as well as Novartis...
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

...years ago. Sales of Kymriah tisagenlecleucel from Novartis AG...
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...roughly in the same league as its partnerships with Eli Lilly and Co. (NYSE:LLY) and Novartis AG...
BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

...By BioCentury Staff The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms...
...XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Xcopri, cenobamate (YKP3089) Cara Therapeutics Inc. Vifor Pharma Ltd. AbbVie Inc. Novartis AG F...
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...managed by Morgan Stanley’s Counterpoint Global, new strategic investor Illumina Inc. (NASDAQ:ILMN) and existing strategic investor Novartis AG...
BioCentury | Mar 28, 2021
Finance

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

...are reversible menin inhibitors, according to Biomea Fusion’s prospectus.Bayer AG (Xetra:BAYN), Johnson & Johnson (NYSE:JNJ), Novartis AG...
BioCentury | Mar 26, 2021
Product Development

Three’s a crowd in SMA sales: Data Byte

...Durkin Wolfe, ASSOCIATE Editor, DATA & Analytics Novartis...
...site was never licensed to manufacture the drug. Novartis AG...
Items per page:
1 - 10 of 10626